Le Lézard
Classified in: Health, Science and technology, Business
Subjects: VEN, ANW


Funding to support BIOiSIMtm computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans

LAUSANNE, Switzerland and SAN FRANCISCO, Jan. 10, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence (AI). VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriSIM contributes to the growth plan of the start-up and will help to expand and establish transformational partnerships with industry and academia using their first-in-class 'virtual drug development engine' BIOiSIMtm. The investment aligns with Debiopharm's focus to invest in digital health solutions that improve the cancer patient journey, transform pharmaceutical R&D, and shift healthcare towards a more patient-centric approach.   

With the financing round led by Morpheus Ventures, Debiopharm Innovation Fund joins new investors including Colorcon Ventures along with existing investors OCA Ventures, Intel Capital, Serra Ventures and Susa Ventures. Founded in 2017 by Jo Varshney, DVM and PhD alongside a cross-functional team of pharmaceutical scientists, software engineers and AI/ML and simulation experts, the start-up offers a range of translational-based solutions, customized for pre-clinical and clinical programs.

"We're moving into a time where AI-based technology will play a critical role in drug development. We absolutely need to reduce the time, costs & risks of drug development in order to be more efficient ? that's exactly what the BIOiSIMtm is proven to do," said Tanja Dowe, CEO of the Debiopharm Innovation Fund. "The value of using this AI-based platform is the potential decrease in the need for animal testing and the acceleration of the pre-clinical, translational stage, helping drug research companies to more quickly select which early-stage medicines will most likely benefit patients and cure their disease."

More than 90% of drugs tested in animals fail to pass human clinical trials, resulting in delayed development and high costs. VeriSIM's BIOiSIM platform, driven by AI and machine learning (ML), de-risks R&D decisions by providing meaningful insights much earlier in the drug development process with unprecedented accuracy and scalability. VeriSIM's platform solves this decade-old translatability problem within the drug development phase and ensures clinical success of drugs intended for highly unmet needs. With its first-in-class platform, VeriSIM is transforming the way pharmaceutical and biotech companies address the most challenging diseases impacting humankind.

About VeriSIM Life

VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to significantly improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The program not only reduces the time and cost of drug discovery and development, it also greatly reduces the need for animal testing that, in the vast majority of cases, does not translate to humans (over 90% of drugs that are currently tested in animals fail to pass human clinical trials). For more information visit: www.verisimlife.com.

Debiopharm's commitment to patients

Debiopharm develops, manufactures and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections. We aim to provide strategic funding and guidance for companies with Smart Data & Digital Health solutions with the ambition to change the way drugs are developed and the way patients are treated. Our growing portfolio company achievements includes 18 FDA clearances or CE marks and 2 IPOs. Since 2018 Debiopharm has invested over USD 120 million, typically leading the investment rounds of its 16 portfolio companies.

For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews and @debiopharmfund

Debiopharm Contact
Dawn Bonine - Communication Manager
[email protected]
Tel: +41 (0)21 321 01 11

These press releases may also interest you

at 09:00
Compass Datacenters and Hines, the global real estate firm, have acquired land in the Milan metro area with the intention to build one of the largest data center campuses in Italy. The 2.3 million square foot Noviglio-located site aims to support...

at 09:00
Black Knight's Optimal Blue Mortgage Market Indices tracked 30-year rates as they pulled back to finish the month at 5.3%, a drop of 49 basis points (bps) from June Total lock volumes were down 14.4% from June, with declines seen in both rate/term...

at 09:00
Mountain Commerce Bancorp, Inc. (the "Company") , the holding company for Mountain Commerce Bank (the "Bank"), today announced that it established a senior revolving line of credit in the maximum amount of $20 million with a financial institution. ...

at 09:00
Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLItm (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be...

at 09:00
HASTA DST Ventures, a sponsor of multifamily real estate DSTs, announced today that its HASTA Multifamily 1 DST has been fully subscribed through the extensive distribution network of its managing broker-dealer, RCX Capital Group. Approximately $55...

at 09:00
ERA HK960, its next-generation POS model, built to drastically improve customer satisfaction via enabling businesses with more flexible, efficient, and secure POS services. Enhanced feature-rich functionality of HK960 coupled with high-end design are...

News published on 10 january 2022 at 13:26 and distributed by: